Most Popular
-
1
Ador CEO denies allegations, accuses Hybe of mistreating NewJeans
-
2
Medical reform committee kicks off despite boycott from doctors
-
3
10-man S. Korea lose to Indonesia to miss out on Paris Olympic football qualification
-
4
Hybe-Ador feud should have limited effect on Hybe's overall performance: analysts
-
5
Second Gimpo civil servant found dead, after apologizing for not finishing work
-
6
DP leader says he will meet Yoon without conditions
-
7
Over 9,000 hotline calls made by stalking victims in 2023
-
8
[Hello India] Hyundai Motor vows to boost 'clean mobility' in India
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050672_0.jpg&u=)
-
9
Monthly users on local streaming platforms outpace Netflix, Disney+
-
10
US will take steps for three-way engagement on nuclear deterrence with S. Korea, Japan: Campbell
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050672_0.jpg&u=)
[DISCLOSURE] Daewha Pharmaceutical (067080) reported on Oct. 12 that it has inked a US$20.12 million five-year contract with NovoSci in United Arab Emirates to supply pharmaceutical products under the condition its products are granted approval for sale in 11 countries including Saudi Arabia.
This amounts to 16.16 percent of its revenue last year.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
This amounts to 16.16 percent of its revenue last year.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
